News

Long-term disease and treatment-related damage reduce the muscle strength and physical capacity of people with ANCA-associated vasculitis. The resulting reduction in physical activity diminishes the quality of life, a study suggests. The study, “Leg muscle strength is reduced and is associated with physical quality of life…

Abnormal antimicrobial traps found in inflammatory lesions from ANCA-associated vasculitis patients might be correlated with disease development, a study suggests. The study, “The formation and disordered degradation of neutrophil extracellular traps in necrotizing lesions of anti-neutrophil cytoplasmic antibody–associated vasculitis,” was published in The American Journal of Pathology.

Lower doses of Rituxan (rituximab) appear to be as safe and effective as the standard Rituxan regimen for inducing remission in ANCA-associated vasculitis (AAV) patients, a retrospective Japanese study suggests. The study, “Low-dose rituximab as induction therapy for ANCA-associated vasculitis,” was published in Clinical Rheumatology.

Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run as high as 350 million — they are thought to impact. Across countries, patients, caregivers and advocates will paint faces, wear…

The use of radiation therapy on granulomatosis with polyangiitis (GPA) patients with cancer should be done with caution to avoid potential complications, a case report suggests. The study, “Lower cranial nerve palsy during radiotherapy for glottic cancer in a patient with Wegener’s granulomatosis: An interesting case report,” appeared in…

PredictImmune has expanded its intellectual propriety portfolio with a new patent approved in Canada covering the company’s methods for predicting the risk of progression among patients with autoimmune diseases, like ANCA-associated vasculitis (AAV) and inflammatory bowel disease (IBD). This follows the 2018 approval of previous patent applications…

G71.01 is, literally, the code for Duchenne muscular dystrophy.  Q93.51 stands for Angelman syndrome, and G40.419 covers generalized and treatment-resistant epilepsies, which groups like Orphanet and the American Epilepsy Society define as including Dravet syndrome. All three designations are among some 70,000 diseases listed in the latest…

A combination of belimumab plus standard maintenance treatment is no better than standard of care alone at delaying relapse in ANCA-associated vasculitis (AAV) patients in remission, a Phase 3 clinical trial shows. However, a subgroup of patients who receive Rituxan (rituximab) as an induction treatment may benefit from belimumab maintenance, the…

In light of upcoming Phase 3 data, ChemoCentryx and Vifor Fresenius Medical Care Renal Pharma have decided not to pursue the conditional approval of avacopan in Europe for patients with ANCA-associated vasculitis. Instead, the companies plan to submit a full (unconditional) marketing approval application for the therapy in 2020 with…

Anti-neutrophil cytoplasmic autoantibody (ANCA) testing is useful for the early diagnosis of ANCA-associated vasculitis (AAV) in patients with central nervous system symptoms, allowing for timely treatment and a better prognosis, but a positive ANCA test could also mean several things besides vasculitis, a review study reports. About 5-15 percent of…